NO921969L - NON-REPLICATING RECOMBINANT MANUFACTURED RETROVIRUS PARTICLES USED AS ANTIVIRAL AGENTS AND IMMUNOGENS - Google Patents
NON-REPLICATING RECOMBINANT MANUFACTURED RETROVIRUS PARTICLES USED AS ANTIVIRAL AGENTS AND IMMUNOGENSInfo
- Publication number
- NO921969L NO921969L NO92921969A NO921969A NO921969L NO 921969 L NO921969 L NO 921969L NO 92921969 A NO92921969 A NO 92921969A NO 921969 A NO921969 A NO 921969A NO 921969 L NO921969 L NO 921969L
- Authority
- NO
- Norway
- Prior art keywords
- hiv
- particles
- recombinant
- produced
- retroviral
- Prior art date
Links
- 239000002245 particle Substances 0.000 title abstract 6
- 241001430294 unidentified retrovirus Species 0.000 title abstract 2
- 239000003443 antiviral agent Substances 0.000 title 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 5
- 208000031886 HIV Infections Diseases 0.000 abstract 4
- 230000001177 retroviral effect Effects 0.000 abstract 4
- 208000030507 AIDS Diseases 0.000 abstract 2
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 2
- 108010008038 Synthetic Vaccines Proteins 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 2
- 230000001900 immune effect Effects 0.000 abstract 2
- 230000000877 morphologic effect Effects 0.000 abstract 2
- 229940124551 recombinant vaccine Drugs 0.000 abstract 2
- 208000003322 Coinfection Diseases 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 101710172711 Structural protein Proteins 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000002131 composite material Substances 0.000 abstract 1
- 108700004025 env Genes Proteins 0.000 abstract 1
- 101150030339 env gene Proteins 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000003362 replicative effect Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Ikke-repllkerende rekombinantfremstilte retrovlrale partikler som har strukturelle, morfologiske og Immunologlske karakteristikker som er meget lignende de til naturlige humane retrovlrus, blir beskrevet. Fremgangsmåten omfatter koekspréssjon av modne retrovirale kjerne- og kappestrukturelle proteiner i mammalske vertsceller slik at de uttrykte retrovlrale proteinene forener seg til sammensatte knoppskytende retrovirale partikler. I en bestemt utførelse blir ikke-replikerende rekombinantfremstilte HIV-1 partikler fremstilt ved koinfeksjon av mammalske vertsceller med et rekombinant vacclnla virus som bærer* de human immunsviktvirus type l (HIV-1) gag og proteasegenene og en rekombinant vacclnla virus som bærer HIV-1 env genet. Disse Ikke-repllkerende rekombinantfremstilte partiklene har Immunologlske. og morfologiske karak- teristikker som er meget nær de til naturlige HIV-1, og er l stand til å blokkere infektivlteten av levende HIV in vitro og er meget sterkt immunogenlske in vlvo. De rekombinantfremstilte HIV-1 partiklene ifølge oppfinn- elsen kan bli anvendt som artlvirale midler og som immunogener i vakslneformuleringer som er effektive l hemming eller forhindring av infeksjon av HIV og/eller utviklingen av ervervet immunsvlktsyndrom (AIDS).Non-replicating recombinantly produced retroviral particles having structural, morphological and immunological characteristics very similar to those of natural human retroviruses are described. The method comprises coexpression of mature retroviral core and envelope structural proteins in mammalian host cells so that the expressed retroviral proteins join into composite bud-shoot retroviral particles. In a particular embodiment, non-replicating recombinant-produced HIV-1 particles are produced by co-infection of mammalian host cells with a recombinant vaccine virus carrying * the human immunodeficiency virus type 1 (HIV-1) gag and the protease genes and a recombinant vaccine virus carrying env gene. These Non-Replicating Recombinant-Prepared Particles have Immunological. and morphological characteristics that are very close to those of natural HIV-1 and are capable of blocking the infectiousness of live HIV in vitro and are highly immunogenic in vivo. The recombinant-produced HIV-1 particles of the invention can be used as artifact agents and as immunogens in vaccine formulations that are effective in inhibiting or preventing infection of HIV and / or the development of acquired immunodeficiency syndrome (AIDS).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43920589A | 1989-11-20 | 1989-11-20 | |
| PCT/US1990/006798 WO1991007425A1 (en) | 1989-11-20 | 1990-11-20 | Non-replicating recombinant-made retroviral particles used as antiviral agents and immunogens |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO921969D0 NO921969D0 (en) | 1992-05-19 |
| NO921969L true NO921969L (en) | 1992-06-26 |
Family
ID=23743729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO92921969A NO921969L (en) | 1989-11-20 | 1992-05-19 | NON-REPLICATING RECOMBINANT MANUFACTURED RETROVIRUS PARTICLES USED AS ANTIVIRAL AGENTS AND IMMUNOGENS |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP0502105A4 (en) |
| JP (1) | JPH05503629A (en) |
| KR (1) | KR920703639A (en) |
| AU (1) | AU636944B2 (en) |
| CA (1) | CA2068713A1 (en) |
| ES (1) | ES2052478T1 (en) |
| FI (1) | FI922277A7 (en) |
| GR (1) | GR930300005T1 (en) |
| HU (1) | HUT60506A (en) |
| NO (1) | NO921969L (en) |
| OA (1) | OA09698A (en) |
| TW (1) | TW216446B (en) |
| WO (1) | WO1991007425A1 (en) |
| ZA (1) | ZA909302B (en) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3034025B2 (en) * | 1989-06-01 | 2000-04-17 | アプライド・バイオテクノロジー・インコーポレーテツド | Self-assembled deficient non-self-replicating virions |
| US5861282A (en) * | 1989-10-16 | 1999-01-19 | Whitehead Institute For Biomedical Research | Non-infectious HIV particles and uses therefor |
| WO1991019803A1 (en) * | 1990-06-19 | 1991-12-26 | Applied Biotechnology, Incorporated | Self assembled, defective, nonself-propagating viral particles |
| DE4124817A1 (en) * | 1991-07-26 | 1993-01-28 | Basf Ag | AQUEOUS POLYMER DISPERSIONS |
| AU672372B2 (en) * | 1991-11-08 | 1996-10-03 | Pharmacia & Upjohn Company | Feline leukemia virus vaccines |
| EP0565794A1 (en) * | 1992-04-14 | 1993-10-20 | British Biotech Pharmaceuticals Limited | Induction of CTL responses |
| US7001759B1 (en) | 1993-01-26 | 2006-02-21 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
| DE69435182D1 (en) | 1993-01-26 | 2009-02-26 | Univ Pennsylvania | Composition for administering genetic material |
| HU219767B (en) | 1993-01-26 | 2001-07-30 | Leslie R. Coney | Compositions and methods for delivery of genetic material into cells |
| GB9304239D0 (en) * | 1993-03-01 | 1993-04-21 | British Bio Technology | Viral particles |
| US5955342A (en) * | 1994-08-15 | 1999-09-21 | Connaught Laboratories Limited | Non-infectious, replication-defective, self-assembling HIV-1 viral particles containing antigenic markers in the gag coding region |
| US6291157B1 (en) | 1998-02-23 | 2001-09-18 | Connaught Laboratories Limited | Antigenically-marked non-infectious retrovirus-like particles |
| US5858838A (en) | 1998-02-23 | 1999-01-12 | Taiwan Semiconductor Manufacturing Company, Ltd. | Method for increasing DRAM capacitance via use of a roughened surface bottom capacitor plate |
| US6080408A (en) | 1994-08-22 | 2000-06-27 | Connaught Laboratories Limited | Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles |
| CN1185811A (en) * | 1995-03-31 | 1998-06-24 | H·沃尔夫 | Antigen presentation system dependent on retrovirus-like particles |
| US6013506A (en) * | 1995-06-05 | 2000-01-11 | Wardley; Richard C. | Feline leukemia virus vaccines |
| US6121021A (en) * | 1997-12-16 | 2000-09-19 | Connaught Laboratories Limited | Constitutive expression of non-infectious HIV-like particles |
| JP4776075B2 (en) | 1998-12-31 | 2011-09-21 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | Modified HIVENV polypeptide |
| AU2221600A (en) | 1998-12-31 | 2000-07-31 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
| AU2487300A (en) | 1998-12-31 | 2000-07-31 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| US8623379B2 (en) | 2000-03-02 | 2014-01-07 | Emory University | Compositions and methods for generating an immune response |
| EP2388015A1 (en) | 2000-03-02 | 2011-11-23 | Emory University | DNA expression vectors and methods of use |
| JP4554887B2 (en) * | 2001-03-08 | 2010-09-29 | アメリカ合衆国 | MVA expressing modified HIV envelope, gag, and pol genes |
| EP1411770A4 (en) | 2001-07-05 | 2006-05-10 | Chiron Corp | POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF |
| US20030170614A1 (en) | 2001-08-31 | 2003-09-11 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
| US9839684B2 (en) | 2011-04-06 | 2017-12-12 | Biovaxim Limited | Pharmaceutical compositions comprising inactivated HIV viral particles and non-pathogenic lactobacilli for the induction of antigen-specific immunotolerance |
| MA42502A (en) | 2015-07-21 | 2018-05-30 | Modernatx Inc | VACCINES AGAINST INFECTIOUS DISEASE |
| AU2016341309A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Cancer vaccines |
| WO2018170256A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Herpes simplex virus vaccine |
| WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
| US12070495B2 (en) | 2019-03-15 | 2024-08-27 | Modernatx, Inc. | HIV RNA vaccines |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4752565A (en) * | 1986-04-07 | 1988-06-21 | The United States Of America As Represented By The Department Of Health And Human Services | Cell line producing AIDS viral antigens without producing infectious virus particles |
| JPH02203783A (en) * | 1989-02-02 | 1990-08-13 | Banyu Pharmaceut Co Ltd | Cloned human t cell forming non-virulent aids virus having antigenicity |
| JP3140757B2 (en) * | 1989-02-06 | 2001-03-05 | デイナ・フアーバー・キヤンサー・インステイテユート | Packaging defective HIV provirus, cell lines and uses thereof |
| GB8923123D0 (en) * | 1989-10-13 | 1989-11-29 | Connaught Lab | A vaccine for human immunodeficiency virus |
| JPH05501201A (en) * | 1989-10-16 | 1993-03-11 | ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ | Non-infectious HIV-1 particles and their uses |
-
1990
- 1990-11-20 EP EP19910900526 patent/EP0502105A4/en not_active Withdrawn
- 1990-11-20 ZA ZA909302A patent/ZA909302B/en unknown
- 1990-11-20 CA CA002068713A patent/CA2068713A1/en not_active Abandoned
- 1990-11-20 WO PCT/US1990/006798 patent/WO1991007425A1/en not_active Ceased
- 1990-11-20 JP JP3501082A patent/JPH05503629A/en active Pending
- 1990-11-20 AU AU69055/91A patent/AU636944B2/en not_active Ceased
- 1990-11-20 KR KR1019920701189A patent/KR920703639A/en not_active Ceased
- 1990-11-20 ES ES91900526T patent/ES2052478T1/en active Pending
- 1990-11-20 HU HU9201659A patent/HUT60506A/en unknown
-
1991
- 1991-01-12 TW TW080100246A patent/TW216446B/zh active
-
1992
- 1992-05-19 NO NO92921969A patent/NO921969L/en unknown
- 1992-05-19 FI FI922277A patent/FI922277A7/en not_active Application Discontinuation
- 1992-05-19 OA OA60209A patent/OA09698A/en unknown
-
1993
- 1993-04-28 GR GR930300005T patent/GR930300005T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| OA09698A (en) | 1993-08-30 |
| FI922277A0 (en) | 1992-05-19 |
| ES2052478T1 (en) | 1994-07-16 |
| NO921969D0 (en) | 1992-05-19 |
| ZA909302B (en) | 1991-09-25 |
| FI922277A7 (en) | 1992-05-19 |
| JPH05503629A (en) | 1993-06-17 |
| HUT60506A (en) | 1992-09-28 |
| WO1991007425A1 (en) | 1991-05-30 |
| EP0502105A1 (en) | 1992-09-09 |
| TW216446B (en) | 1993-11-21 |
| EP0502105A4 (en) | 1993-02-24 |
| KR920703639A (en) | 1992-12-18 |
| AU636944B2 (en) | 1993-05-13 |
| HU9201659D0 (en) | 1992-08-28 |
| AU6905591A (en) | 1991-06-13 |
| GR930300005T1 (en) | 1993-04-28 |
| CA2068713A1 (en) | 1991-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO921969L (en) | NON-REPLICATING RECOMBINANT MANUFACTURED RETROVIRUS PARTICLES USED AS ANTIVIRAL AGENTS AND IMMUNOGENS | |
| DK33190A (en) | HIV-3 RETROVIRUS AND ITS USE | |
| Pinter et al. | Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1 | |
| Gallaher | Detection of a fusion peptide sequence in the transmembrane protein of human immunodeficiency virus | |
| Haigwood et al. | Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralizing antibodies | |
| Binley et al. | Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins | |
| Karacostas et al. | Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector. | |
| JP3152433B2 (en) | Vaccine and immunotherapy for preventing HIV infection | |
| NO863803L (en) | Vaccines and Immunoassays for Acquired Immunodeficiency Syndrome (AIDS). | |
| WO1999027958A3 (en) | Hiv-1 tat, or derivatives thereof for prophylactic and therapeutic vaccination | |
| DK0495811T3 (en) | Production of genetically engineered vaccines against AIDS and other retroviral diseases | |
| FR2773156A1 (en) | NOVEL ANTI-RETROVIRAL IMMUNOGENS (TOXOIDS), NOVEL PREPARATION METHODS AND APPLICATION TO AIDS PREVENTION AND TREATMENT | |
| ES2140380T3 (en) | DNA SEQUENCES THAT CODE MODIFIED RETROVIRIC POLYPEPTIDES AND VACCINES THAT CONTAIN THEM OR ADDED THEREOF. | |
| DE60026199T2 (en) | Synthetic genes for gagpol and their uses | |
| CA2230925A1 (en) | Fusion protein delivery system and uses thereof | |
| JP2004509601A5 (en) | ||
| De Rossi et al. | Synthetic peptides from the principal neutralizing domain of human immunodeficiency virus type 1 (HIV-1) enhance HIV-1 infection through a CD4-dependent mechanism | |
| SE9903031D0 (en) | Peptide mixture and vaccine against a chronic viral infection | |
| MY104530A (en) | Nonreplicating recombinant-made retroviral particles useful as anti-viral agents and as immunogens for pro- phylaxis and therapy against human retroviruses. | |
| AU630861B2 (en) | Recombinant hiv-2 polypeptides | |
| SE8701628D0 (en) | MEANS OF ANALYSIS MM | |
| EP0327180A3 (en) | Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1 | |
| WO2022035860A3 (en) | Replication-competent adenovirus type 4-hiv env vaccines and their use | |
| Soutschek et al. | Purification of a recombinantly produced transmembrane protein (gp41) of HIV I | |
| Vogt et al. | Heterologous HIV-2 challenge of rhesus monkeys immunized with recombinant vaccinia viruses and purified recombinant HIV-2 proteins |